SNDX News and Press, Syndax Pharmaceuticals Inc. From 10/13/23

2023-10-13 14:52:22 ET Summary Syndax Pharmaceuticals, Inc. reported positive results from its phase 1/2 trial using revumenib to treat relapsed/refractory leukemia patients. The trial met its primary endpoint with a complete remission rate of 23%, significantly higher than the cu...

2023-10-11 13:35:35 ET More on Syndax Syndax Pharmaceuticals: Positive Axatilimab Phase 2 Results Syndax Pharmaceuticals, Inc. (SNDX) Q2 2023 Earnings Call Transcript Biggest stock movers today: Arch Resources, Coinbase Global and more Syndax Pharma falls aft...

2023-10-02 07:47:20 ET More on Syndax Syndax Pharmaceuticals: Positive Axatilimab Phase 2 Results Syndax Pharmaceuticals, Inc. (SNDX) Q2 2023 Earnings Call Transcript Biggest stock movers today: Syndax Pharmaceuticals, Coinbase Global and more Syndax and Incy...

Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis PR Newswire – Trial met its primary endpoint with a CR/CRh rate of 23% ...

2023-10-02 05:30:06 ET Related stories Coinbase: The Shift From Exchange To A Comprehensive Financial Powerhouse Coinbase: Bullish Seasonality, But Is That Enough? Coinbase Global, Inc. (COIN) Barclays 2023 Global Financial Services Conference (Transcript) Up...

Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023 PR Newswire WALTHAM, Mass. , Sept. 29, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SN...

2023-09-29 15:00:29 ET More on the markets Historical Evidence Between Real Yields Suggests Further Slump For SPY Interest Rates Won't Be Higher For Longer: SPY Implications Rate environment today 'rhymes with 2008' - J.P. Morgan's Kolanovic Stocks in midst o...

2023-09-08 10:42:03 ET Summary Syndax is making strides in the adoption of entinostat, a cancer therapeutic used in combination with immune checkpoint therapies. Syndax reported an increase in operating expenses in Q2 2023, but remains financially stable with cash reserves of $418...

Syndax Announces Participation at the Citi 18th Annual BioPharma Conference PR Newswire WALTHAM, Mass. , Aug. 31, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer th...

2023-08-11 14:55:42 ET BofA Securities has initiated coverage of Kura Oncology ( NASDAQ: KURA ) with a buy rating, commenting that it sees the stock as undervalued given the long-term revenue potential of its lead drug candidate ziftomenib, which is being developed as a treatment fo...